Find Clinical Trials & Studies
RESPIR-102
I'm Interested!
A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomonas aeruginosa Lung Infection
- Sex: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase I
- Conditions Being Studied: Lung, Cystic Fibrosis (CF)
Study Purpose
The main purpose of this study is to see whether inhaling this combination of drugs in RSP 1502 has an acceptable safety profile and works better compared to inhaling tobramycin alone when treating participants with CF and chronic Pseudomonas aeruginosa lung infection.
Who Can Participate
Age: 18 years and older
- UH IRB: SITE00002058
- StudyID: 2023-01232
- ClinicalTrials.gov: NCT06016088
I'm Interested!
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422